Xencor
Develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
Launch date
Employees
Market cap
AUD2.3b
Enterprise valuation
AUD1.7b (Public information from Sep 2024)
Share price
$21.2 XNCR
Monrovia California (HQ)
Authorizing premium user...